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Abstract
Background: The international guidelines recommend the administration of trimethoprim-sulfamethoxazole (TMP-SMX)
as Pneumocystis jiroveci pneumonia (PJP) prophylaxis for six months after transplantation. The aim of this study is to
evaluate the influence of TMP-SMX prophylaxis on the occurrence of asymptomatic bacteriuria (ASB) and urinary tract
infections (UTIs) as cystitis and allograft pyelonephritis (AGPN) and its impact on the antimicrobial resistance pattern of
causative microorganisms.
Methods: We have conducted a retrospective before-after study in adult renal allograft recipients with one year
follow-up after transplantation. We compared the (“after”) group that received TMP-SMX as PJP prophylaxis to
the (“before”) group that did not receive it.
Results: In total, 343 renal allograft recipients were analysed, of whom 212 (61.8 %) received TMP-SMX as PJP
prophylaxis. In this study, 63 (18.4 %) did only develop ASB without UTI, 26 (7.6 %) developed cystitis and 43
(12.5 %) developed AGPN. The remaining 211 (61.5 %) renal allograft recipients did not develop any bacteriuria
at all. Multivariable Cox proportional regression analysis indicated that TMP-SMX as PJP prophylaxis was not
associated with reduced prevalence of ASB (Hazard ratio (HR) = 1.52, 95 % CI = 0.79–2.94, p = 0.213), nor with
reduced incidence of cystitis (HR = 2.21, 95 % CI = 0.76–6.39, p = 0.144), nor AGPN (HR = 1.12, 95 % CI = 0.57–
2.21, p = 0.751). Among the group receiving TMP-SMX as PJP prophylaxis there was a trend was observed in
increase of both amoxicillin (86 % versus 70 %) and TMP-SMX (89 % versus 48 %) resistance which already
appeared within the first 30 days after TMP-SMX exposure.
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Conclusions: Among renal allograft recipients, administration of TMP-SMX as PJP prophylaxis does not prevent
ASB nor UTI, however it is associated with tendency towards increased amoxicillin and TMP-SMX resistance.
Keywords: Asymptomatic bacteriuria, Urinary tract infections, Renal transplantation, Trimethoprim-
sulfamethoxazole, Pneumocystis jiroveci pneumonia prophylaxis
Background
Bacteriuria which is the most common infectious com-
plication after renal transplantation [1] is categorised in
asymptomatic bacteriuria (ASB) and urinary tract infec-
tions (UTIs) as cystitis and allograft pyelonephritis
(AGPN). The incidence of bacteriuria is the highest
within the first three months after renal transplantation
[2] and many risk factors for bacteriuria in general and
for both ASB and UTI separately have been described in
the medical literature [3]. Administration of low dose
antibiotics as UTI prophylaxis is commonly imple-
mented within different patient groups. For example,
among non-pregnant women experiencing recurrent
UTIs, low dose antimicrobial prophylaxis has been
shown to be effective in preventing UTIs [4]. Renal allo-
graft recipients also receive low dose antibiotics, which
is trimethoprim-sulfamethoxazole (TMP-SMX) intended
as Pneumocystis jiroveci pneumonia (PJP) prophylaxis
for six months after transplantation as recommended by
international guidelines [2, 5].
The aim of this study is to evaluate the influence of
TMP-SMX intended as PJP prophylaxis on both the
prevalence of ASB and incidence of UTIs among renal
allograft recipients. In addition to this, we also evaluate
the impact of TMP-SMX as PJP prophylaxis on the anti-
microbial resistance pattern of the microorganisms caus-
ing these bacteriuria events.
Methods
Study design
Retrospective before-after study with adult renal allo-
graft recipients. The administration of TMP-SMX as PJP
prophylaxis was implemented in June 2007. The “before”
group consisted of those renal allograft recipients that
did not receive TMP-SMX and the “after” group con-
sisted of those who did receive it. We compared the
group that received TMP-SMX as PJP prophylaxis to the
group that did not receive it. Renal allograft recipients
transplanted between July 2005 (start of implementing
external stented ureterocystostomy) and 2009 were
analysed, with one year follow-up after transplantation
for developing bacteriuria.
Definitions
ASB was defined as a bacteriuria event (at least 105
colony-forming units (CFU)/ml) without any clinical
symptoms suggestive for UTI [2, 6]. UTI was categorised
into cystitis and AGPN. Cystitis was defined as the pres-
ence of leukocyturia (≥10 leukocytes per high power
field microscopy analysis), bacteriuria (≥ 104 CFU/ml)
with symptoms of the lower urinary tract (urgency,
frequency and dysuria) without fever. AGPN was defined
as the presence of leukocyturia, bacteriuria (≥104
colony-forming units (CFU)/ml) and fever (>38.0 °C) [2]
with exclusion of other infectious cause for fever.
Delayed graft function was defined as the requirement
of dialysis within the first week after transplantation [7].
Acute rejection episode was diagnosed through a renal
allograft biopsy.
Cytomegalovirus (CMV) disease was defined as a posi-
tive quantitative polymerase chain reaction (PCR) with
end organ involvement resulting in fever, gastrointestinal
disease, pneumonia, hepatitis nephritis and/or retinitis
as described by the guidelines [8, 9].
Renal allograft surgery procedures and medications
The renal allograft was positioned into the iliac fossa
through an extraperitoneal approach. Cephamandole was
routinely administered as peroperative antimicrobial
prophylaxis. All renal allograft recipients received external
stented ureterocystostomy with an 8 French catheter. This
stent was inserted in the bladder through a suprapubic
puncture and positioned in the pelvis of the renal allograft
and was routinely removed after five days. The Foley cath-
eter, which was inserted pre-operatively, was removed
after seven days if urine leakage was excluded by cystogra-
phy on that same day.
All renal allograft recipients receive triple immunosup-
pressive therapy which includes steroids combined with
mycophenolate mofetil or mycophenolic acid and a cal-
cineurin inhibitor, mostly tacrolimus but alternatively
cyclosporine. If necessary, induction therapy with basi-
liximab was given pre-operatively according to the inter-
national guidelines [10].
Valganciclovir was provided for a period of six months
after renal transplantation. Trimethoprim-sulfamethoxazole
as PJP prophylaxis at a daily dose of 480 mg was imple-
mented in June 2007. After transplantation, all renal allo-
graft recipients received this prophylaxis for a period of six
months. Recipients being allergic for, or having other con-
traindications for TMP-SMX did not receive TMP-SMX
prophylaxis.
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Patient follow-up after transplantation
After discharge from the renal transplantation ward, all
renal transplant recipients were frequently followed
within our outpatient clinics. During the first three
months after transplantation, all renal allograft recipients
were seen twice per week on average. Hereafter, renal
allograft recipients were seen once a month within the
first year after transplantation.
Surveillance for bacteriuria occurred through screen-
ing for leukocyturia within the urine sediment. In case
of leukocyturia, a urine culture was taken. A urine cul-
ture was also taken in case of fever or urinary tract
symptoms. On average, every renal allograft recipient
received 22 urine sediment analyses/urine cultures
within the first year after transplantation. Only ASB
episodes occurring within the first three months after
transplantation were treated. Hereafter, ASB was not
systematically treated since the international guideline
does not give a consensus of management [2, 11].
Susceptibility testing
Susceptibility testing was performed either using disk
diffusion according to EUCAST criteria or using the
VITEK2® system (BioMérieux, France). Interpretation of
susceptibility results was performed using EUCAST
breakpoints. Microorganisms were classified as “resistant”
against a certain antimicrobial agent if the MIC reported
by the VITEK2® system or the zone diameter using disk
diffusion exceeded the breakpoint for susceptibility.
Antimicrobial resistance pattern and TMP-SMX exposure
To evaluate the impact of TMP-SMX as PJP prophylaxis
on the antimicrobial resistance pattern of the causative
microorganisms, we determined the frequency of resist-
ance to amoxicillin, TMP-SMX, amoxicillin-clavulanic
acid, ciprofloxacin and nitrofurantoin among E. coli iso-
lates according to TMP-SMX exposure. These E. coli
isolates were subcategorised in three arbitrary time-
frames according to the time between transplantation
and urine culture. The “early” time-frame consisted of E.
coli isolates cultured within the first 30 days after trans-
plantation, those cultured between 31 and 180 days were
categorised within the “intermediate” time-frame. The
third time-frame consisted of E. coli isolates cultured
between 181 and 365 days were categorised into “late”
time-frame.
Each UTI was considered as a unique episode. Mul-
tiple ASB episodes in one renal allograft recipient were
considered as unique in case of different genus of the
cultured causative microorganism. In case of multiple
ASB episodes with the same causative microorganism;
these cultures were considered as unique if there was at
least one negative urine culture between them.
Statistical analysis
Statistical analysis was performed by using SPSS version
21 software (IBM SPSS Statistics for Windows, Version
21.0. Armonk, NY: IBM Corp.). Figures were made with
GraphPad Prism version 5.00 for windows, GraphPad
Software, San Diego California USA.
Continuous variables were expressed as the mean with
its standard deviation in case of normal distribution. In case
of non-normal distribution, the median and (25–75 %)
interquartile range (IQR) were noted. In case of normal dis-
tribution, Student’s t-test was used to compare continuous
variables between two groups. In case of non-normal distri-
bution Mann Whitney-U test was used. Categorical vari-
ables were expressed as proportion (n) and percentage (%),
and were compared using Chi-square test.
To determine the risk factors for ASB and UTI (cystitis
or AGPN), we compared the group that did not develop
any bacteriuria at all (reference group) to the group that
developed respectively only ASB, cystitis or AGPN. These
events were analysed separately with Cox proportional
hazard model analysis.
To determine the hazard of developing respectively
ASB or UTI according to TMP-SMX as PJP prophylaxis
use, we first performed univariable Cox proportional
hazard model in which ASB or UTI were the dependent
variable and TMP-SMX the independent variable. In the
first multivariable model we adjusted for the group
differences stratified according to TMP-SMX use. In the
second multivariable model we adjusted for both the
group differences according to TMP-SMX use and also
for variables significantly associated with developing
respectively ASB or UTI obtained by the univariable
COX proportional hazard model. The results of these
analysis were reported as hazard ratio (HR) with its 95 %
confidence interval (95 % CI). The hazards were propor-
tional over time, we tested this by defining the two
groups as a function over time variable, which we divided
into two equal periods. A p value smaller than 0.05 was
considered as statistically significant.
Results
Comparison of the group without and with TMP-SMX as
PJP prophylaxis
Table 1 gives an overview of the entire group according
to TMP-SMX as PJP prophylaxis use. In total, 343 renal
allograft recipients with one-year follow-up were analysed,
212 (61.8 %) received TMP-SMX as PJP prophylaxis in the
“after” group. In total 17 renal allograft recipients trans-
planted after June 2007 did not receive TMP-SMX as result
of allergy/intolerance and were classified in the “no TMP-
SMX” group.
There were three significant differences between the
group without and with TMP-SMX as PJP prophylaxis;
diabetes mellitus (p = 0.007), indwelling urological catheters
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(p = 0.002) and tacrolimus based immunosuppressive ther-
apy (p < 0.001) were more prevalent in the group receiving
TMP-SMX as PJP prophylaxis in comparison to the group
without it.
ASB and UTI rate according to TMP-SMX administration
Table 1 also displays the amount of bacteriuria according
to TMP-SMX exposure. Within one year after transplant-
ation, 211 (61.5 %) out of 343 renal allograft recipients did
Table 1 Comparison between the group without and with TMP-SMX as PJP prophylaxis
Total No TMP-SMX TMP-SMX P value
N = 343 (100 %) N = 131 (38.2 %) N = 212 (61.8 %)
Variables
Age recipient 52 (40–61) 52 (40–59) 52 (39–61) 0.420
BMI recipient 25.2 +/−4.5 24.7 +/− 4.2 25.5 +/−4.6 0.128
Female gender 152 (44.3) 65 (49.6) 87 (41.0) 0.120
Diabetes Mellitus (a) 94 (27.4) 25 (19.1) 69 (32.5) 0.007
Age donor 50 (40–57) 49 (39–57) 51 (41–57) 0.232
Allograft from deceased donor 215 (62.7) 83 (63.4) 132 (62.3) 0.839
Delayed graft function 109 (31.8) 42 (32.1) 67 (31.6) 0.930
Acute rejection 80 (23.3) 31 (23.7) 49 (23.1) 0.925
Indwelling urological catheter (b) 53 (15.5) 10 (7.6) 43 (20.3) 0.002
First transplantation 294 (85.7) 113 (86.3) 181 (85.4) 0.821
CMV disease 26 (7.6) 13 (9.9) 13 (6.1) 0.197
Maintenance therapy <0.001
Tacrolimus-MMF-steroids 205 (59.8) 49 (37.4) 156 (73.2)
MMF-cyclosporine-steroids 38 (11.1) 28 (21.4) 10 (4.7)
MA-cyclosporine-steroids 100 (29.2) 54 (41.2) 46 (21.7)
Induction therapy
Basiliximab 216 (63.0) 82 (62.6) 134 (63.2) 0.909
Primary renal disease
Hypertension 88 (25.7) 23 (17.6) 65 (30.7)
Cystic renal disease 49 (14.3) 18 (13.7) 31 (14.6)
IgA nephropathy 28 (8.2) 15 (11.5) 13 (6.1)
Diabetes 20 (5.8) 7 (5.3) 13 (6.1)
Focal segmental glomerulosclerosis 27 (7.9) 11 (8.4) 16 (7.5)
Reflux and anatomical abnormalities 25 (7.3) 11 (8.4) 14 (6.6)
Glomerulonephritis 26 (7.6) 10 (7.6) 16 (7.5)
Unknown origin 27 (7.9) 12 (9.2) 15 (7.1)
Others 53 (15.5) 24 (18.3) 29 (13.7)
Bacteriuria outcomes:
No bacteriuria 211 (61.5) 94 (71.7) 117 (55.2) 0.002
Bacteriuria 132 (38.5) 37 (28.2) 95 (44.8)
Subtype of bacteriuria
- only ASB 63 (18.4) 17 (13.0) 46 (21.7)
- cystitis 26 (7.6) 5 (3.8) 21 (9.9)
- AGPN 43 (12.5) 15 (11.5) 28 (13.2)
Continuous variables are depicted as mean with +/− standard deviation or as median with (25–75 %) interquartile range. Nominal variables are depicted as the
total number analysed with its percentage (%). AGPN allograft pyelonephritis, ASB asymptomatic bacteriuria, CI confidence interval, CMV cytomegalovirus, MA
mycophenolic acid, MMF mycophenolate mofetil, TMP-SMX trimethoprim-sulfamethoxazole
a: The variable “diabetes mellitus” includes type 1, type 2 diabetes and new onset of diabetes after transplantation (NODAT), irrespective of whether it was the
primary disease which led to renal failure. b: The variable “Indwelling urological catheter” represents Foley catheter, nephrostomy catheter and
intermittent self-catheterisation
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not develop any episode of bacteriuria at all, 63 (18.4 %)
recipients developed only ASB, 26 (7.6) developed cystitis
and 43 (12.5) developed AGPN. In comparison to the
group without TMP-SMX as PJP prophylaxis, bacteriuria
more prevalent among the group that did receive it
(44.8 % versus 28.2 %, p = 0.002).
Within one year after transplantation, the cumulative
amount of unique bacteriuria episodes was 316 within the
entire study group; 79 episodes (25.2 %) occurred in the
group without TMP-SMX prophylaxis and 236 episodes
(74.9 %) occurred in the group with this prophylaxis.
Risk factors for ASB and UTIs
Table 2 displays the univariable analysis of the variables
associated with developing ASB, cystitis or AGPN
respectively compared to the reference group that did
not developed any bacteriuria at all. Risk factors for ASB
were advanced age of the recipient (HR = 1.02, 95 %
CI = 1.00–1.04, p = 0.029), female gender (HR = 2.01,
95 % CI = 1.22–3.33, p = 0.007) advanced age of the
donor (HR = 1.03, 95 % CI = 1.01–1.05, p = 0.010) and
indwelling urological catheters (HR = 12.94, 95 % CI =
7.76–21.57, p < 0.001).
Risk factors for cystitis were diabetes mellitus (HR =
1.13, 95 % CI = 1.45–6.75, p = 0.004), BMI of recipient
(HR = 1.09, 95 % CI = 1.01–1.17, p = 0.027), receiving a
renal allograft obtained from deceased donor (HR = 5.28,
95 % CI = 1.59–17.60, p = 0.007), delayed graft function
(HR = 2.41, 95 % CI = 1.12–5.21, p = 0.025) and indwell-
ing urological catheters (HR = 8.22, 95 % CI = 3.09–
21.90, p < 0.001). The only identified risk factor for
AGPN was the presence of an indwelling urological
catheter (HR = 11.24, 95 % CI = 5.92–21.33, P < 0.001).
Influence of TMP-SMX as PJP prophylaxis on the occurrence
of ASB and UTIs
Since the group without and with TMP-SMX as PJP
prophylaxis were not comparable to each other on the
variables diabetes mellitus, the presence of urological
catheters and the subtype of the immunosuppressive
therapy (Table 1), we performed multivariable Cox pro-
portional hazard regression analysis in which we also
adjusted for these three variables (Tables 3, 4 and 5).
In the univariable Cox proportional hazard regression
analysis TMP-SMX was associated with developing ASB
(HR = 2.03, 95 % CI = 1.17–3.55, p = 0.012) as shown in
Table 3. After correcting for both the group differences
according to TMP-SMX prophylaxis administration and
for univariable risk factors for ASB (Table 3), TMP-SMX
was not associated with reduced occurrence of ASB
(HR = 1.52, 95 % CI = 0.79–2.94, p = 0.213).
In the univariable Cox proportional regression analysis,
TMP-SMX was associated with developing cystitis (HR =
3.12, 95 % CI = 1.18–8.28, p = 0.022), however after
adjustment for both the group differences according to
TMP-SMX prophylaxis administration and univariable risk
factors for developing cystitis (Table 4), TMP-SMX did not
prevent cystitis (HR = 2.21, 95 % CI = 0.76–6.39, p = 0.144).
Administration of TMP-SMX as PJP prophylaxis was not
associated with reduced incidence of AGPN in both uni-
variable model (HR = 1.46, 95 % CI = 1.78–2.73, p = 0.239)
nor in the adjusted model (HR = 1.12, 95 % CI = 0.57–2.21,
p = 0.751) (Table 5).
To illustrate this, we additionally analysed the sub-
group that did not develop diabetes, and never had in-
dwelling urological catheter in situ (n = 217). For this
subgroup, time between transplantation and respectively
ASB, cystitis and AGPN is displayed in Fig. 1.
Causative microorganisms and antimicrobial resistance
pattern
In total 315 unique bacteriuria episodes were identified
within one year after transplantation. The majority of
the causative microorganisms of the bacteriuria events
were by Escherichia coli (E. coli) and Enterococcus spp.
(Table 6).
Figure 2a displays the percentage of resistance for the
five antibiotics among E. coli isolates. Among the E. coli
isolates cultured from the group that received TMP-
SMX as PJP prophylaxis, there was a tendency towards
higher resistance rate for both amoxicillin (86 % versus
70 %) and TMP-SMX (89 % versus 48 %) compared to
the group that did not receive it. No differences in resist-
ance rates of amoxicillin-clavulanic acid, ciprofloxacin or
nitrofurantoin were observed.
To evaluate the change in amoxicillin and TMP-SMX
resistance in course of time after transplantation, we
compared the percentage of resistance against these two
antibiotics among E. coli isolates cultured within the first
30 days after transplantation (“early” time-frame), be-
tween 31 and 180 days (“intermediate” time-frame) and
finally within 181–365 days (“late” time-frame) after
transplantation (Fig. 2b and c). Among the group with
TMP-SMX as PJP prophylaxis, the E. coli isolates cul-
tured within the first 30 days after transplantation, had a
higher resistance rate to amoxicillin (80 % versus 50 %)
and TMP-SMX (83 % versus 13 %), in comparison to E.
coli isolates within the same time frame but without
TMP-SMX exposure.
Discussion
We were particularly interested whether TMP-SMX as
PJP prophylaxis had any influence on the occurrence of
ASB and UTI after renal transplantation. The administra-
tion of TMP-SMX as PJP prophylaxis was not associated
with lower ASB prevalence nor lower UTI incidence.
Furthermore, after TMP-SMX exposure, a tendency
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Table 2 Univariable comparison between the group that did not develop any bacteriuria at all and the group that developed respectively only ASB, cystitis or AGPN
No bacteriuria versus only ASB No bacteriuria versus cystitis No bacteriuria versus AGPN
No bacteriuria (REF)
N = 211 (61.5 %)
Only ASB
N = 63 (18.4 %)
Univariable analysis
HR (95 % CI)
P value Cystitis
N = 26 (7.6 %)
Univariable analysis
HR (95 % CI)
P value AGPN
N = 43 (12.5 %)
Univariable analysis
HR (95 % CI)
P value
Variables
TMP-SMX prophylaxis 117 (55.5) 46 (73.0) 2.03 (1.17–3.55) 0.012 21 (80.8) 3.12 (1.18–8.28) 0.022 28 (65.1) 1.46 (0.78–2.73) 0.239
Age of recipient 51 (38–59) 54 (46–64) 1.02 (1.00–1.04) 0.029 56 (44–60) 1.03 (1.00–1.06) 0.108 54 (38–62) 1.01 (0.99–1.04) 0.282
Female gender 85 (40.3) 38 (60.3) 2.01 (1.22–3.33) 0.007 13 (50.0) 1.43 (0.67–3.10) 0.357 16 (37.2) 1.18 (0.63–2.18) 0.610
Diabetes Mellitus (a) 49 (23.2) 19 (30.2) 1.37 (0.80–2.35) 0.250 13 (50.0) 1.13 (1.45–6.75) 0.004 13 (30.2) 1.39 (0.73–2.67) 0.320
BMI of recipient 25.0 +/−4.30 25.3 +/−4.35 1.02 (0.96–1.08) 0.576 27.0 +/−6.7 1.09 (1.01–1.17) 0.027 25.0 +/−3.9 1.00 (0.94–1.08) 0.932
Age of donor 49 (40–56) 53 (43–65) 1.03 (1.01–1.05) 0.010 51 (40–58) 1.00 (0.97–1.03) 0.738 48 (37–57) 1.00 (0.98–1.02) 0.992
Allograft from deceased donor 122 (57.8) 50 (79.4) 1.22 (0.73–2.03) 0.453 23 (88.5) 5.28 (1.59–17.60) 0.007 30 (69.8) 1.61 (0.84–3.09) 0.152
Delayed graft function 60 (28.4) 19 (30.2) 1.08 (0.63–1.84) 0.790 13 (50.0) 2.41 (1.12–5.21) 0.025 17 (39.5) 1.56 (0.85–2.87) 0.156
Acute rejection 43 (20.4) 19 (30.2) 1.56 (0.91–2.67) 0.109 8 (30.8) 1.64 (0.71–3.78) 0.244 10 (23.3) 1.12 (0.55–2.28) 0.751
Indwelling urological catheter (b) 5 (2.4) 28 (44.4) 12.94 (7.76–21.57) <0.001 5 (19.2) 8.22 (3.09–21.90) <0.001 15 (34.9) 11.24 (5.92–21.33) <0.001
First transplantation 180 (85.3) 54 (85.7) 1.04 (0.52–2.11) 0.907 22 (84.6) 0.97 (0.34–2.83) 0.961 38 (88.4) 1.27 (0.50–3.22) 0.619
CMV disease 16 (7.6) 6 (9.5) 1.26 (0.54–2.92) 0.592 1 (3.8) 0.50 (0.07–3.66) 0.491 3 (7.0) 0.88 (0.28–2.87) 0.842
Maintenance therapy
Tacrolimus + MMF + steroids 122 (57.8) 41 (65.1) 1.00 18 (69.2) 1.00 24 (55.8) 1.00
MMF + cyclosporine + steroids 22 (10.4) 8 (12.7) 1.02 (0.48–2.19) 0.851 2 (7.7) 0.65 (0.15–2.81) 0.567 6 (14.0) 1.30 (0.53–3.19) 0.563
MA + cyclosporine + steroids 67 (31.8) 14 (22.2) 0.65 (0.35–1.19) 0.164 6 (23.1) 0.63 (0.25–1.57) 0.319 13 (30.2) 0.97 (0.49–1.90) 0.919
Induction therapy
Basiliximab 134 (63.5) 39 (61.9) 0.94 (0.56–1.56) 0.805 43 (52.3) 0.58 (0.27–1.24) 0.159 30 (69.8) 1.28 (0.67–2.46) 0.455
Continuous variables are depicted as mean with +/− standard deviation or as median with (25–75 %) interquartile range. Nominal variables are depicted as the total number analysed with its percentage (%). AGPN
allograft pyelonephritis, ASB asymptomatic bacteriuria, CI confidence interval, CMV cytomegalovirus, MA mycophenolic acid, MMF mycophenolate mofetil, NA not applicable, HR hazard ratio, REF reference,
TMP-SMX trimethoprim-sulfamethoxazole
a: The variable “diabetes mellitus” includes type 1, type 2 diabetes and new onset of diabetes after transplantation (NODAT), irrespective of whether it was the primary disease which led to renal failure













towards increased amoxicillin and TMP-SMX resist-
ance was observed.
In this study, we observed that 18.4 % developed only
ASB and 20.1 % developed UTI; of which 7.6 % devel-
oped cystitis and 12.5 % AGPN. In the medical litera-
ture, the incidence of bacteriuria shows a great variety as
result of large differences in the used diagnostic criteria
and frequency of routine urine culture testing [1, 12]
The prevalence of ASB ranges between 17 % [13] and
40 % [14] within the first year after transplantation.
Cystitis incidence has been reported at 12.2 % during
three year follow-up [15] while the AGPN incidence
ranges between 13 % [16] and 16.5 % [17] during four to
ten year follow-up time.
Compared to the group without TMP-SMX as PJP
prophylaxis, the group receiving TMP-SMX prophylaxis
had significantly more bacteriuria as result of higher
prevalence of diabetes and indwelling urological cathe-
ters. Increased diabetes prevalence in the group receiv-
ing TMP-SMX prophylaxis can most likely be explained
by the more frequently administration of tacrolimus,
which has decreased insulin sensitivity as a common side
effect [18]. In addition to this, indwelling urological
catheters are a great risk factor for bacteriuria; it has
been estimated that there is a daily risk of 5 % for devel-
oping bacteriuria after catheterisation and approximately
70 % of catheterised patients develop bacteriuria after
14 days [19, 20]. As result of these three differences,
we performed multivariable Cox regression analysis in
which we adjusted for these three variables and for the
variables associated with developing respectively ASB,
cystitis or AGPN. Within these multivariable models,
administration of TMP-SMX as PJP prophylaxis was
not associated with reduced occurrence of ASB, cyst-
itis or AGPN. Comparable outcome has been observed
by another research group which reported that the use
of one double-strength tablet of TMP-SMX three
times a week did not prevent UTI defined as cystitis
and pyelonephritis [21]. However, another study [22]
demonstrated that the addition of 30-day of ciprofloxa-
cin to TMP-SMX prophylaxis lowered the incidence of
UTI in comparison to TMP-SMX prophylaxis alone. Inter-
estingly, no difference was observed in the incidence of
pyelonephritis.
The observation that TMP-SMX does not prevent
ASB nor UTIs could likely be explained by the great
potency of gram negative bacteria for developing TMP-
SMX resistance after exposure to it. Indeed, it has been
shown that TMP-SMX exposure results in TMP-SMX
resistance in E. coli, which is even observed after one
month of TMP-SMX administration [23].
The first clinical trials evaluating the effect of antimicro-
bial prophylaxis on the incidence of bacteriuria among
renal allograft recipients were performed in late eighties
and early nineties of the last millennium [24–26]. In these
studies, TMP-SMX was used as prophylaxis. The inter-
variability of TMP-SMX dose between these studies was
large and ranged between 480 mg once a day to 960 mg
twice a day. Also the duration of antimicrobial prophylaxis
administration differed. A systematic review [27] which
also included these studies concluded that antimicrobial
prophylaxis indeed reduces bacteriuria and bacteraemia.
However the analysed original intervention studies did
not mention the clinical symptoms associated with
Table 5 Univariable and multivariable Cox regression analysis for
developing AGPN within one year after transplantation according
to TMP-SMX prophylaxis administration
Outcome AGPN P value
HR (95 % CI)
TMP-SMX: univariable model (a) 1.46 (0.78–2.73) 0.239
TMP-SMX: first multivariable model (b) 1.12 (0.57–2.21) 0.751
a: Univariable model: adjusted for only TMP-SMX use
b: First multivariable analysis: adjusted for diabetes mellitus, subtype of
immunosuppressive therapy and indwelling urological catheters. Since
indwelling urological catheters were the only risk factors for AGPN no second
multivariable analysis has been performed
Table 3 Univariable and multivariable Cox regression analysis for
developing ASB within one year after transplantation according to
TMP-SMX prophylaxis administration
Outcome ASB P value
HR (95 % CI)
TMP-SMX: univariable model (a) 2.03 (1.17–3.55) 0.012
TMP-SMX: first multivariable model (b) 1.18 (0.63–2.20) 0.600
TMP-SMX: second multivariable model (c) 1.52 (0.79–2.94) 0.213
a: Univariable model: adjusted for only TMP-SMX use
b: First multivariable analysis: adjusted for diabetes mellitus, subtype of
immunosuppressive therapy and indwelling urological catheters
c: Second multivariable analysis: adjusted for diabetes mellitus, subtype of
immunosuppressive therapy, indwelling urological catheters, age of recipient
and donor and female gender
Table 4 Univariable and multivariable Cox regression analysis for
developing cystitis within one year after transplantation according
to TMP-SMX prophylaxis administration
Outcome cystitis P value
HR (95 % CI)
TMP-SMX: univariable model (a) 3.12 (1.18–8.28) 0.022
TMP-SMX: first multivariable model (b) 2.29 (0.79–6.67) 0.127
TMP-MSX: second multivariable model (c) 2.21 (0.76–6.39) 0.144
a: Univariable model: adjusted for only TMP-SMX use
b: First multivariable analysis: adjusted for diabetes mellitus, subtype of
immunosuppressive therapy and indwelling urological catheters
c: Second multivariable analysis: adjusted for diabetes mellitus subtype of
immunosuppressive therapy, indwelling urological catheters, BMI of recipient,
type of renal allograft (obtained from a deceased versus living donor) and
delayed graft function
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bacteriuria. Therefore in these studies, it is difficult to de-
termine whether TMP-SMX at prophylactic dose prevents
ASB or UTI, or possibly both.
The second aim of our study was to evaluate the impact
of TMP-SMX as PJP prophylaxis on the antimicrobial re-
sistance pattern of the causative microorganisms. Among
E. coli isolates cultured within the first 30 days after trans-
plantation, there was an increase in both amoxicillin and
TMP-SMX resistance after TMP-SMX exposure. This co-
resistance of TMP-SMX with amoxicillin has also been
described in other studies [23, 28] and is a common find-
ing, since the resistance genes of these antimicrobials are
located on the same plasmid [28–30]. However as a limi-
tation, our study was not powered to observe statistical
significant differences in antimicrobial resistance accord-
ing to TMP-SMX exposure, therefore no statistical tests
were performed in this analysis.
We also observed that the difference in amoxicillin resist-
ance with and without TMP-SMX did not differ anymore
among E. coli isolates cultured between 181 and 365 days
after renal transplantation reflecting the antimicrobial re-
sistance drift, since the likelihood of exposure to antibiotics
increases in course of time. Indeed, excessive exposure to
antibiotics is the greatest contributing factor for developing
antimicrobial resistance [31]. However, among the E. coli
isolates cultured between 181 and 365 days after transplant-
ation, there was still a difference noticeable in TMP-SMX
resistance with and without TMP-SMX exposure, indicat-
ing that TMP-SMX resistance developed after subsequent
six months of TMP-SMX exposure might be able to persist
for a longer period of time after discontinuation.
In this study we analysed renal allograft recipients
transplanted between 2005 and 2009; a possibility exist
that the increase of amoxicillin and TMP-SMX resist-
ance according to TMP-SMX exposure could be influ-
enced by an increase in antimicrobial resistance rate in
course of time (background resistance). To evaluate this,
we compared our data about the increase in amoxicillin
and TMP-SMX resistance among E. coli isolates within
this study, to those E. coli isolates cultured within unse-
lected hospital departments across the Netherlands be-
tween 2005 and 2009. Within this time span, amoxicillin
resistance rate among E. coli steadily increased from 44
to 48 % [32]. The background TMP-SMX resistance did
not increase above 30 % in 2009 [32]. This increase in
background antimicrobial resistance is smaller than the
increase in antimicrobial resistance observed in our study
population, which could be attributed to the six months
exposure to TMP-SMX as PJP prophylaxis.
The unique aspect of this study is the comparison of a
relative large group of renal allograft recipients who re-
ceived TMP-SMX intended as PJP prophylaxis to a group
who did not receive it. The limitations of our study are
Table 6 Causative microorganisms of the unique bacteriuria
episode according to TMP-SMX prophylaxis administration
Entire cohort No TMP-SMX TMP-SMX
N = 315 (100 %) N = 79 (25.2 %) N = 236 (74.9 %)
Escherichia coli 128 (40.6) 31 (39.2) 97 (41.1)
Enterococcus spp. 70 (22.2) 18 (22.8) 52 (22.0)
Enterobacter spp. 15 (4.8) 7 (8.9) 8 (3.4)
Klebsiella spp. 20 (6.3) 2 (2.5) 18 (7.6)
Proteus spp. 12 (3.8) 6 (7.6) 6 (2.6)
Pseudomonas spp. 38 (12.1) 7 (8.9) 31 (13.1)
Others 32 (10.2) 8 (10.1) 24 (10.2)
ASB cystitis
No bacteriuria ASB cystitis AGPN total
No TMP-SMX n (%) 78 (77.2) 11 (10.9) 3 (3.0) 9 (8.9) 101 (100)
TMP-SMX n (%) 81 (69.8) 14 (12.1) 10 (8.6) 11 (9.5) 116 (100)
Total n (%) 159 (73.3) 25 (11.5) 13 (6.0) 20 (9.2) 217 (100)
AGPN
Fig. 1 Analysis of the subgroup without diabetes nor any urological catheters in situ (n = 217). Kaplan Meijer curves for developing ASB, cystitis or
AGPN according to TMP-SMX administration as PJP prophylaxis
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related to the retrospective and non-interventional setup.
In retrospective studies, the determination of ASB preva-
lence is less accurate than determining UTI incidence
because UTI is diagnosed by the presence of predefined
clinical UTI symptoms accompanied by bacteriuria, while
the rate of ASB is heavily influenced by the frequency of
routine urine culturing [33]. Therefore, the likelihood for
ASB detection increases by frequent urine culturing. To
exclude potential bias caused by the frequency of testing,
we analysed each ASB patient only once to determine risk
factors for ASB. Another limitation of this study may be
the policy of not systematically treating ASB episodes
occurring three months after transplantation. Due to the
retrospective setup, it is difficult to determine which
circumstances resulted in the decision to treat a certain
ASB episode occurring after three months transplantation.
Conclusions
Our retrospective before-after study indicates that TMP-
SMX prophylaxis does not have an additional bacteriuria
preventive property besides PJP prevention. However it
may have a certain contribution to an increase in amoxi-
cillin and TMP-SMX resistance. Despite great advances
made in renal transplantation medicine, there is still a
need for effective UTI preventive measures among renal
allograft recipients.
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